Antibe’s subsidiary Citagenix has launched PentOS OI Max, a bone graft substitute for oral and maxillofacial surgery in Canada.
The new product is part of Antibe’s portfolio of PentOS OI bone graft products. PentOS OI Max is an inductive collagen matrix that can be mixed with the clinician’s choice of patient derived concentrates including stem cells and blood components.
The company claims that osteoinductivity has been demonstrated in each lot in both in vivo and vitro assays at independent laboratories.
In vitro testing showed that bone morphogenetic protein (BMP) levels were up to 40 times than that of the control. BMP is a naturally occurring growth factor found in the human body and plays a crucial role in bone formation.
On the other hand, in vivo testing showed that all the five elements of bone formation are present in the PentOS OI grafts including chondrocytes, osteocytes, bone marrow cells, cartilage, and new bone.
High cell viability and proliferation were noted in in vitro studies as well.
Antibe’s CEO Dan Legault said: “Citagenix continues to augment its portfolio with the addition of high-quality products that support optimal patient outcomes at a competitive price point.
“Being the ‘portfolio-of-choice’ for dentists and oromaxillofacial surgeons is important to our global growth strategy and is supported by an active business development funnel.”
Antibe Therapeutics is a Canada-based pharmaceutical company that develops medicines for pain and inflammation. Its flagship drug is the ATB-346, a hydrogen sulfide-releasing derivative of naproxen. The drug has been developed to address osteoarthritis.
The company plans to extend the drug’s application to rheumatoid arthritis and other diseases that are being treated with non-steroidal anti-inflammatory drugs (NSAIDs). Antibe acquired Citagenix in 2015, which is a developer and distributor of regenerative medicine.